Blog

Arndt Vogel: Durable complete responses to PD-1 blockade

Photo taken from Arndt Vogel/X

Jun 5, 2024, 02:53

Arndt Vogel: Durable complete responses to PD-1 blockade

Nina Niu Sanford shared a post by Arndt Vogel on X/Twitter:

“Truly incredible. In practice we don’t see 100% response rate to IO for dMMR locally advanced rectal cancer.

What is different here?”

Quoting Arndt Vogel’s post:

“Durable complete responses to PD-1 blockade alone in mismatch repair deficient locally advanced rectal cancer.
100% cCR, no relapse and no additional therapy
20 patients with sustained response of 12 monts
ctDNA as an early marker of response
Just amazing efficacy…”

Source: Nina Niu Sanford/X and Arndt Vogel/X

Dr. Nina Niu Sanford is an Assistant Professor and Chief of Gastrointestinal Radiation Oncology at Harvard/Brigham and Women’s Hospital/Massachusetts General Hospital. She specializes in treating gastrointestinal cancers and actively participates in clinical trials combining high-dose radiation therapy with immunotherapy. Additionally, she researches healthcare access disparities and conducts pan-cancer outcomes research using large databases.

Arndt Vogel, MD, is a Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and Endocrinology at Hannover Medical School. Leading the GI-Cancer Center and the Center for Personalized Medicine, his research focuses on translational and clinical studies in gastrointestinal cancer.
He’s actively engaged in various societies including ESMO, ASCO, and EASL. Additionally, he chairs the Hepatobiliary Cancer Study Group of the AIO, contributing significantly to clinical oncology in Germany. Within ESMO, he serves on the Guidelines Steering Committee.